不同剂量伊贝沙坦对高血压病患者尿微量蛋白含量的影响

目的观察伊贝沙坦对高血压病患者动态血压和尿微量蛋白含量的影响。方法92例高血压病同时有尿微量蛋白异常的患者随机分为两组,伊贝沙坦150mg/d组与300mg/d组,疗程4 周。观察治疗前后动态血压值及尿微量白蛋白(Alb)、尿免疫球蛋白G(IgG)、尿转铁蛋白(TRF)、尿N-乙酰-B-D氨基葡萄糖苷酶(NAG)水平的变化及其与药物剂量的关系。结果(1)伊贝沙坦150mg/d组与300mg/d组治疗后血压均显著降低(P<0.01),两组降压效果相似;(2)伊贝沙坦治疗后尿微量蛋白排泄明显减少(P<0.01),其中以300mg/d组作用更为显著。结论伊贝沙坦除具良好的降压作用外,还能明显减少尿微量蛋白的排泄,对肾脏起到保护作用;随药量增加,改善尿微量蛋白作用更为明显,但降压效果差异无显著性。

Influence of irbesartan on Microalbuminuria of Essential Hypertensive Patients

Objective To investigate the effect of irbesartan on dynamic blood pressure and mi-croalbuminuria of essential hypertensive patients. Methods Ninety-two cases with essential hypertension were divided into randomly two groups: irbesartan 150mg and irbesartan 300mg, treated for 4 weeks respectively. Dynamic blood pressure, parameters of renal function such as uAlb, ulgG, uTRF and uNAG were measured before and after treatment. Results (1) After receiving irbesartan a reduce of blood pressure was significant(P<0. 01), but reducation in blood pressure was equivalent in two groups. (2) Urinary microalbumin excretions were significantly less than those before treatment in two groups (P<0. 01). Irbesartan 300mg group was more effective than other group in the decrease of albuminuria (P<0. 05). Conclusion Irbesartan can decrease not only the blood pressure, but also decrease the microalbumin in urine. In addition, the drug also protect kidney functions.